Company news
Spero Therapeutics, Inc. news in 2021
Spero Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Spero Therapeutics Announces Third Quarter 2021 Operating Results and Provides Business Update
November 9, 2021
Spero Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
November 2, 2021
Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis
October 27, 2021
Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors
October 11, 2021
Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners® for Up to $125 Million
September 29, 2021
Spero Therapeutics Announces Second Quarter 2021 Operating Results and Provides Business Update
August 4, 2021
Spero Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
July 28, 2021
Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206
June 29, 2021
Spero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of SPR206
June 14, 2021
Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206
May 16, 2021
Spero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business Update
May 5, 2021
Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update
March 10, 2021
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021
March 2, 2021
Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial
February 4, 2021
Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr
January 20, 2021